Werewolf Therapeutics, Inc. (HOWL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | - | - | - | 1,143 |
| Research and development | 13,143 | 13,120 | 12,528 | 15,271 |
| General and administrative | 4,399 | 4,871 | 4,596 | 4,832 |
| Total operating expenses | 17,542 | 17,991 | 17,124 | 20,103 |
| Operating loss | -17,542 | -17,991 | -17,124 | -18,960 |
| Other income, net | 11 | 168 | 97 | 1,613 |
| Interest income | 850 | 997 | 1,598 | 1,793 |
| Interest expense | 1,301 | 1,263 | 1,244 | 1,142 |
| Loss on extinguishment of debt | - | - | - | -553 |
| Total other (expense) income | -440 | -98 | 451 | 1,711 |
| Net loss | -17,982 | -18,089 | -16,673 | -17,249 |
| Net loss per common share, basic (in usd per share) | -0.4 | -0.4 | -0.38 | -0.4 |
| Net loss per common share, diluted (in usd per share) | -0.4 | -0.4 | -0.38 | -0.43 |
| Weighted-average common shares outstanding, basic (in shares) | 44,981,746 | 44,827,159 | 43,704,836 | 43,521,406 |
| Weighted-average common shares outstanding, diluted (in shares) | 44,981,746 | 44,827,159 | 43,704,836 | 44,043,184 |